A groundbreaking UK study has revealed that severe hyperphagia, often referred to as ‘hidden hunger,’ remains largely underdiagnosed in cases of rare obesity. This oversight can significantly impact patients’ health and quality of life, underscoring the critical need for improved awareness and diagnostic practices. The research highlights the challenges faced by individuals suffering from rare forms of obesity, who often experience uncontrollable hunger that significantly disrupts their daily lives. Despite advances in medical understanding, hyperphagia in these patients is frequently missed by healthcare providers, leading to inadequate care and management. Rhythm Pharmaceuticals has responded by announcing new data presentations at a major 2026 conference, aiming to address these gaps in understanding. This new attention to the issue is expected to influence both future research directions and treatment approaches, offering hope for better management of hyperphagia in rare obesity forms.
Stock TitanNew data shows a significant rise in compliance actions by Regulatory Authorities, ACECQA Snapshot reveals
August 17, 2026
In a recent development, new data from the ACECQA Snapshot indicates a notable increase in compliance actions taken by Regulatory Authorities in 2026. The surge